|
| Index | - | P/E | - | EPS (ttm) | -0.24 | Insider Own | 0.10% | Shs Outstand | 37.94M | Perf Week | 8.97% |
| Market Cap | 27.03M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 21.45M | Perf Month | -13.07% |
| Income | -9.30M | PEG | - | EPS next Q | - | Inst Own | 17.80% | Short Float | 1.23% | Perf Quarter | 13.11% |
| Sales | 0.14M | P/S | 187.73 | EPS this Y | 16.70% | Inst Trans | -1.00% | Short Ratio | 4.81 | Perf Half Y | 1.80% |
| Book/sh | -0.30 | P/B | - | EPS next Y | - | ROA | -343.00% | Target Price | - | Perf Year | -39.08% |
| Cash/sh | 0.01 | P/C | 67.58 | EPS next 5Y | - | ROE | 89.40% | 52W Range | 0.52 - 1.77 | Perf YTD | -29.02% |
| Dividend | - | P/FCF | - | EPS past 5Y | 12.10% | ROI | -566.60% | 52W High | -56.29% | Beta | 1.41 |
| Dividend % | - | Quick Ratio | 0.20 | Sales past 5Y | -38.70% | Gross Margin | - | 52W Low | 49.88% | ATR | 0.10 |
| Employees | 5 | Current Ratio | 0.20 | Sales Q/Q | -82.90% | Oper. Margin | - | RSI (14) | 48.89 | Volatility | 15.84% 11.62% |
| Optionable | No | Debt/Eq | - | EPS Q/Q | -35.10% | Profit Margin | - | Rel Volume | 0.51 | Prev Close | 0.73 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | May 13 AMC | Payout | - | Avg Volume | 54.94K | Price | 0.77 |
| Recom | - | SMA20 | -1.05% | SMA50 | -6.76% | SMA200 | -7.87% | Volume | 28,194 | Change | 5.99% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite